Elissa Cote is the senior vice president and chief strategy and business development officer at Mallinckrodt Pharmaceuticals. She has responsibility for corporate strategy, licensing, M&A and alliance management, and is a member of Mallinckrodt’s senior leadership team.
When AstraZeneca (AZ) announced in 2019 that it was officially retiring the MedImmune brand, questions naturally arose about whether the U.K. pharma giant would continue the legacy MedImmune support for the BioHealth Capital Region’s (BHCR) life science ecosystem.
Top Biopharma Talent Acquisition Experts Share Strategies for Hiring and Retaining Employees in 2020
The biotech industry continues to grow rapidly across the nation, especially in the BHCR. The region’s strategy for hiring and retaining employees is a key driver of the BHCR’s steady, sustained growth.
Former MedImmune Employees Leading In the BioHealth Capital Region and Beyond In a recent conversation someone shared the quote “You can’t throw a stone in the BioHealth Capital Region and [….]
5 Questions with Stephanie Duatschek, Biopharma Executive Management Consultant “5 Questions With……” is a new BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to [….]
5 Questions with Jennifer Butler, Executive Vice President and General Manager of Innate Pharma U.S.
5 Questions with Jennifer Butler, Executive Vice President and General Manager of Innate Pharma U.S. “5 Questions With……” is a new BioBuzz series where we reach out to interesting people [….]
5 Questions With John Trainer, CFO, NexImmune, Inc. “5 Questions With……” is a new BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share [….]
BHCR Retains #4 Ranking in GEN’s Top 10 U.S. Biopharma Clusters – Here’s Why. “Top 3 By 2023” has been the slogan for the Biohealth Capital Region (BHCR) over the [….]
BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time March 12, 2019 In 1942, Austrian economist Joseph Schumpeter wrote, “ …industrial mutation—if I may use that biological [….]
Viela Bio’s Spinout Story Reveals A Roadmap for Growth Ahead November 6, 2018 In order: Elizabeth Parsons (Member, Mintz Levin), Aaron Ren (Head of BD and Operations, Viela Bio), Christian [….]